RESULTS:
Forty-one burn patients, with severe neuropathic pain refractory to pharmacologic therapy, proximal nerve decompression, laser resurfacing, and fat grafting, underwent hypertrophic scar excision in the lower extremities (31), upper extremities (23), trunk (8), and face (1) , an average of 2.2 years post-burn. Neuromas were identified on pathology for 33 excisions. Wound healing complications occurred in 10.0% of procedures (12 complications in 10 patients), including dehiscence (6.7% of cases) and recurrence of neuroma (11.5% of cases). At a mean of 20.2 months postop, 53.3% of patients reported definite improvement, 36.6% had somewhat improved, 5.0% had no improvement, and 5.0% were worse.
CONCLUSION:
In patients with severe neuropathic burn pain, refractory to aggressive medical, pharmacologic, and surgical interventions, the presence of a neuroma may be the cause of neuropathic pain, and scar tissue may impact cutaneous sensory nerves. Excision of the hypertrophic scar and neuroma can provide long-term relief and decrease the use of pain medication; as such, surgery is indicated in the majority of these carefully selected patients.
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We performed a retrospective analysis of clinical and cost data from ReSurge International, a nonprofit organization providing plastic and reconstructive surgical care in LMICs. Using both the clinical and cost data, we conducted a (1) cost-effectiveness and (2) costbenefit analysis to examine the economic sustainability of the interventions. We used WHO-CHOICE thresholds to evaluate the cost-effectiveness of the interventions. 2 We assigned a disability weight for each surgical case to calculate disability-adjusted life years (DALYs). The costeffectiveness was reported as cost per DALY-averted. This represents the cost to avert a particular amount of disability. Additionally, we stratified cost-effectiveness by procedure type. We adopted a value of a statistical life year approach to cost-benefit analyses to calculate the economic benefit.
RESULTS:
We examined data from 22 mission trips performed between 2015 and 2017. We analyzed a total of 778 surgical cases performed in eight different countries. Procedures performed included orofacial cleft repair (28%), burn contracture release (25%), eye ptosis repair (12%), excision for abnormal soft-tissue masses (13%), and other reconstructive surgeries (22%). The cost per DALY-averted for each trip ranged from USD$57-$11,364 and was less than three times the GDP per capita in the host country. Thus, according to WHO-CHOICE thresholds, all of these interventions are considered cost-effective or very cost-effective. When separating the procedures, orofacial cleft repair was the most cost-effective (cost per DALYaverted: USD$31). The net economic benefit ranged from USD$66,7404 to $16,046,027 for each trip. The total net economic benefit of plastic surgical outreach trips was USD$118,778,585.
CONCLUSION:
Plastic surgery is economically sustainable in a resource-limited setting. These results indicate a substantial economic benefit of mission trips, indicating a return on investment for surgical procedures performed in LMICs. Furthermore, this study highlights the importance of adherence to a standardized checklist to collect data on mission trips performed in LMIC to provide a comprehensive framework to assess the health and economic impact of surgical mission trips in the future.
